- Home
- EDN vs BBNX Comparison
EDN vs BBNX Comparison
Compare EDN & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDN | BBNX |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2007 | 2025 |
Fundamental Metrics
Financial Performance| Metric | EDN | BBNX |
|---|---|---|
| Price | $30.53 | $31.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $28.55 |
| AVG Volume (30 Days) | 100.0K | ★ 1.0M |
| Earning Date | 08-11-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $1,678,118,877.00 | $88,570,000.00 |
| Revenue This Year | $32.93 | $52.13 |
| Revenue Next Year | $24.64 | $36.16 |
| P/E Ratio | $20.03 | ★ N/A |
| Revenue Growth | 3.69 | ★ 67.01 |
| 52 Week Low | $14.38 | $8.89 |
| 52 Week High | $48.44 | $32.71 |
Technical Indicators
Market Signals| Indicator | EDN | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 49.08 | 61.56 |
| Support Level | $30.93 | $30.32 |
| Resistance Level | $32.48 | $31.89 |
| Average True Range (ATR) | 1.67 | 1.56 |
| MACD | -0.22 | 0.08 |
| Stochastic Oscillator | 44.13 | 82.59 |
Price Performance
Historical ComparisonAbout EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires mainly to residential, commercial, industrial, and public service.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.